Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090539 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
A Phase 1 study of Relapsed/Refractory Non-Hodgkin Lymphoma, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 308
- Enrollment target
- 20
- Study locations
NCT06090539: Recruiting Phase 1 study of Relapsed/Refractory Non-Hodgkin Lymphoma, sponsored by Bristol-Myers Squibb.
NCT06090539 is a Phase 1 study of Relapsed/Refractory Non-Hodgkin Lymphoma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 308 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (413% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06090539, a Phase 1 study of Relapsed/Refractory Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 308 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
Conditions Studied
Interventions
- DRUG Mosunetuzumab
- DRUG Rituximab
- DRUG BMS-986458
- DRUG Glofitamab/Obinutuzumab
Study Locations (20)
Other
- CHU SAINT ELOI - Departement Hematologie Clinique - Montpellier
- Hôpital Saint-Louis - Paris
- Institut Claudius Regaud - Toulouse
Florida
- Local Institution - 0068 - Jacksonville
- Local Institution - 0027 - Tampa
New York
- Local Institution - 0047 - Lake Success
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Mayo Clinic in Arizona - Phoenix - Phoenix
California
- City of Hope Comprehensive Cancer Center - Duarte
Kansas
- Local Institution - 0014 - Fairway
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic in Rochester, Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2023-12-29 |
| Est. Completion | 2028-10-28 |
| Phase | Phase 1 |
What NCT06090539 shows while recruiting
NCT06090539 is an interventional study that assigns participants to a tested intervention. The registered 308 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (413% higher).
The record links to 1 condition, with Relapsed/Refractory Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Mosunetuzumab is the first listed.
NCT06090539 names 20 study sites across 16 states, led by Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06090539 about?
NCT06090539 is a clinical study titled "A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas". The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in pa...
What is the current status of trial NCT06090539?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 308 participants. The study started on 2023-12-29. Estimated completion is 2028-10-28.
What conditions does trial NCT06090539 study?
This clinical trial studies the following conditions: Relapsed/Refractory Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06090539?
The interventions under investigation include: Mosunetuzumab (DRUG), Rituximab (DRUG), BMS-986458 (DRUG), Glofitamab/Obinutuzumab (DRUG).
Who is sponsoring clinical trial NCT06090539?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06090539 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06090539's enrollment target sits among peer trials
308 122nd of 2000 higher than 1,878 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06233942 · 308 participants · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
- NCT06319248 · 308 participants · Phase 2
MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI